Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ESPR Stock Surges 44% in a Month: Here's What You Need to Know
Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—PFLC, ESPR, LKSB, and MKC
Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Esperion Therapeutics, Inc. (NASDAQ: ESPR)
Shareholder Alert: Ademi LLP investigates whether Esperion Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders
ESPR Stock Alert: Halper Sadeh LLC is Investigating Whether Esperion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
Archimed to take Esperion Therapeutics private in $1.1 billion deal
Esperion to be Acquired by ARCHIMED
Esperion to be Acquired by ARCHIMED
Esperion to Report First Quarter 2026 Financial Results on May 7
Esperion Therapeutics Highlights 38% Revenue Growth, Enbumyst Launch Plan at Needham Conference
Esperion Therapeutics (ESPR) Down 10% Since Last Earnings Report: Can It Rebound?
Esperion Therapeutics, Inc. $ESPR Shares Purchased by JPMorgan Chase & Co.
Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics
Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
Esperion Therapeutics Touts 38% Revenue Growth, Corstasis Deal and 2026 Cash-Gen Path at Conference
Esperion's Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia
Brokerages Set Esperion Therapeutics, Inc. (NASDAQ:ESPR) Target Price at $8.25
ESPR's Q4 Earnings Lag Estimates, Revenues Beat, Stock Down
Esperion Therapeutics, Inc. (ESPR) Q4 2025 Earnings Call Transcript
Esperion Therapeutics (ESPR) Misses Q4 Earnings Estimates
Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M
Esperion Therapeutics, Inc. (ESPR) M&A Call Transcript
Esperion Acquires Enbumyst Maker Corstasis
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
Esperion Therapeutics (ESPR) Earnings Expected to Grow: Should You Buy?
Principal Financial Group Inc. Trims Stake in Esperion Therapeutics, Inc. $ESPR
Esperion to Participate in The 2026 Citizens Life Sciences Conference
Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Recommendation of “Moderate Buy” from Analysts
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion Therapeutics, Inc. (ESPR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
Esperion Therapeutics (NASDAQ:ESPR) Shares Gap Up – Here’s What Happened
Stock Traders Purchase Large Volume of Call Options on Esperion Therapeutics (NASDAQ:ESPR)
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Esperion Therapeutics, Inc. (ESPR) Presents at Jefferies London Healthcare Conference 2025 Transcript
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
Wasatch Ultra Growth Fund Q3 2025 Top Contributors And Detractors
Esperion Therapeutics, Inc. (ESPR) Discusses Breaking the Statin Intolerance Barrier and Closing the Care Gap in Cardiovascular Health Transcript
Esperion Therapeutics: Still An Attractive Risk/Reward Narrative As The Earnings Clock Ticks Toward Profitability
ESPR's Q3 Earnings Lag Estimates, Revenues Rise Y/Y, Stock Down
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion Therapeutics, Inc. (ESPR) Q3 2025 Earnings Call Transcript
Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates